lsta1
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2023 (NCT05712356)
Timeline
Indications
Studied for
- Appendiceal Neoplasms · Phase 1
- Bile Duct Neoplasms · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 2
- Laryngeal Neoplasms · Phase 2
- Mouth Neoplasms · Phase 2
- Neoplasms · Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1/Phase 2
- Peritoneal Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
- Fibronectin receptor betaINHIBITOR
ITGB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06592664 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Lisata Therapeutics, Inc. |
| NCT06216561 | Phase 1 | Nov 30, 2023 | University of California, San Diego |
| NCT05712356 | Phase 2 | Aug 24, 2023 | Lisata Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lisata Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2023 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1